AgingResearch.NewsJoin free

20(s)-protopanaxadiol

Intervention

1 paper2 findings

PubChem 11213350ChEBI 75950

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Natural Science Foundation of China and 1 more
  • Model organisms1

Outcomes

2

Healthspan

upin worms1

1 study

  1. 20(s)-protopanaxadiol improves healthspan in worms.

    “It also improved healthspan in aging worms by ameliorating locomotor deficits and suppressing lipofuscin accumulation.”

    Model organisms

    20(S)-protopanaxadiol prolongs lifespan and enhances stress resistance in Caenorhabditis elegans via the insulin/IGF-1 signaling pathway

    Frontiers in pharmacology14 Oct 2025

Lifespan

upin worms1

1 study

  1. 20(s)-protopanaxadiol extends lifespan in worms.

    “20(S)-PPD could significantly extend Caenorhabditis elegans (C. elegans) lifespan without affecting food intake and reproductive output.”

    Model organismsnormal conditions

    20(S)-protopanaxadiol prolongs lifespan and enhances stress resistance in Caenorhabditis elegans via the insulin/IGF-1 signaling pathway

    Frontiers in pharmacology14 Oct 2025

Latest

Related